Connect with us

Spread & Containment

2022 Blavatnik Regional Awards for Young Scientists Honorees announced

NEW YORK – September 21, 2022 – The Blavatnik Family Foundation and the New York Academy of Sciences today announced the three Winners and six Finalists…



NEW YORK – September 21, 2022 – The Blavatnik Family Foundation and the New York Academy of Sciences today announced the three Winners and six Finalists of the 2022 Blavatnik Regional Awards for Young Scientists. The Awards honor outstanding postdoctoral scientists from academic research institutions across New York, New Jersey, and Connecticut. The announcement comes during the National Postdoctoral Association’s 13th annual celebration of 2022 National Postdoc Appreciation Week, which recognizes the significant contributions that postdoctoral scholars make to U.S. research and discovery.

Credit: Blavatnik Awards/ New York Academy of Sciences

NEW YORK – September 21, 2022 – The Blavatnik Family Foundation and the New York Academy of Sciences today announced the three Winners and six Finalists of the 2022 Blavatnik Regional Awards for Young Scientists. The Awards honor outstanding postdoctoral scientists from academic research institutions across New York, New Jersey, and Connecticut. The announcement comes during the National Postdoctoral Association’s 13th annual celebration of 2022 National Postdoc Appreciation Week, which recognizes the significant contributions that postdoctoral scholars make to U.S. research and discovery.


The Blavatnik Regional Awards jury, consisting of distinguished scientists and engineers from across the New York region, selected one Winner in each of the three categories who will receive a $30,000 unrestricted prize and two Finalists in each category who will be awarded $10,000 each. In the 2022 competition, there were 158 outstanding nominations from 26 academic institutions in the New York metropolitan region (Tri-State area). The 2022 Blavatnik Regional Awards Winners and Finalists will be honored at the 2022 New York Academy of Sciences Gala at Cipriani 25 Broadway on November 14, 2022. Due to pandemic delays, the 2021 Blavatnik Regional Awards honorees will also be celebrated at that event.


“It is my great pleasure to congratulate this year’s Blavatnik Regional Awards Winners and Finalists,” said Len Blavatnik, Founder and Chairman of Access Industries, head of the Blavatnik Family Foundation, and member of the President’s Council of the New York Academy of Sciences. “The Tri-State area is one of the most exciting scientific ecosystems, attracting outstanding postdoctoral talent from around the world. We look forward to great discoveries from these exceptional young scientists in the future.”


Nicholas B. Dirks, the New York Academy of Sciences’ President and CEO, said, “Postdocs are the quiet force driving scientific research. Without their tireless efforts and enormous sacrifice, most of our new discoveries and inventions in science, medicine, and engineering would not happen. We are proud to salute the 2022 Blavatnik Regional Awards Winners and Finalists as part of our Academy’s tribute to National Postdoc Appreciation Week.”


The 2022 Blavatnik Regional Awards Winners in the three award categories are:


Life Sciences: Josefina del Mármol, PhD, nominated by The Rockefeller University

Molecular biologist Dr. Josefina del Mármol has provided the first structural snapshot of odor detection by an olfactory receptor (OR) from any species at the near-atomic level. At the molecular level, odors are composed of combinations of millions of chemically diverse compounds that animals must sense with only tens or hundreds of ORs. Through the use of cryo-electron microscopy, molecular biologist del Mármol determined the atomic structure of an insect OR and how multiple odorants, including the insect repellent DEET, interact with it in a structural and biochemical fashion. Del Mármol’s discoveries provided the first conclusive evidence that DEET targets insect ORs and supports the hypothesis that DEET “scrambles” the olfactory signal to “confuse” mosquitos. Del Mármol has recently joined the faculty at Harvard Medical School.


Physical Sciences & Engineering: Xiaolong Liu, PhD, nominated by Cornell University

Condensed Matter physicist Dr. Xiaolong Liu has developed new types of microscopic imaging techniques, like the high-speed scanning Josephson-tunneling microscopy technique (SJTM), that explore vexing problems in quantum physics. The new microscope Liu developed led to the very first atomic-scale observation of Cooper-pair density waves—standing waves of electron pairs in a superconductor, similar to the standing wave of a plucked string. Liu engages in another exciting area of physics—electron superfluids—an electronic version of a fluid, much like water, that contains no resistance to flow. Using SJTM, Liu showed that jet-speeds of up to 3,000 meters per second (up to MACH 9) can be reached by electron pairs in a superfluid. The new imaging methodologies being developed by Liu are equipping scientists with novel tools to explore exciting new problems in quantum physics. Liu has recently joined the faculty at the University of Notre Dame.


Chemistry: Wen Zhang, PhD, nominated by Cornell University

Organic chemist Dr. Wen Zhang has harnessed electrochemistry to promote reactions of carbon-based compounds without relying on rare materials historically used in chemistry. Chemists use these transition metals—such as palladium or nickel—to manipulate the bonds between carbon atoms in organic molecules. Zhang is advancing the burgeoning field of electrochemical synthesis, which uses electricity to promote reactions instead of transition metals, by demonstrating the ability to manipulate carbon bonds in ways that are required to synthesize drugs and other medicinally relevant compounds. Zhang’s work is sparking a wave of new methods for synthesizing chemicals, and may prove critical in making chemistry more sustainable in the future.


The following postdoctoral researchers have been named Finalists in their respective categories:


Life Sciences

Andrew Bridges, PhD, nominated by Princeton University

Bacteria commonly resist threats by forming multicellular structures known as biofilms. Biofilms are surface-attached, multicellular communities of bacteria that offer protection from antimicrobials and assist in the transmission of bacterial diseases. Microbiologist Dr. Andrew Bridges has pioneered studies on the lifecycles of bacterial biofilms, developing a novel microscopy assay whereby he can visualize, in real-time, the biofilm lifecycle of Vibrio cholerae, the bacteria that causes the global disease, cholera. He focuses on the understudied dispersal phase of the biofilm lifecycle whereby cells exit the biofilm to start another one. By incorporating molecular and genetic techniques, Bridges identified three important steps that drive V. cholerae biofilm dispersal. These steps include signal transduction via a previously uncharacterized molecular signaling pathway, digestion of the components that hold cells together in the biofilms, and finally, bacterial locomotion. Bridges’ discoveries could lead to new strategies to control biofilm dispersal with the potential to halt the spread of disease. Bridges has recently joined the faculty at Carnegie Mellon University.


Daniel Zegarra-Ruiz, PhD, nominated by Memorial Sloan Kettering Cancer Center

The gut microbiome consists of trillions of microbes that impact host immune processes involved in health and disease. Immunologist Dr. Daniel Zegarra-Ruiz found that during early development, gut bacteria act as a template to educate and increase the number microbiota-specific T cells. These important immune cells recognize gut bacteria and help mount appropriate immune responses to future infection. Zegarra-Ruiz also discovered how changes in the gut microbiome can impact colorectal cancer whereby exposing mice to the bacteria Escherichia coli after tumor initiation can amplify tumor growth, but exposure before tumor formation can lead to improved outcomes. Zegarra-Ruiz’s research is critical to understand the impact of bacteria on the immune system and the consequences it has on cancer growth and autoimmune diseases.


Physical Sciences & Engineering

Jiaoyang Huang, PhD, nominated by New York University

Mathematician Dr. Jiaoyang Huang has tackled the most fundamental questions that lie at the heart of Random Matrix Theory (RMT)—a mathematical theory that has widespread use in modern fields of engineering and science. His remarkable results and influence across the field of mathematics will have impacts well beyond the field, including quantum chaos and communication and social networks. Huang has also made fundamental breakthroughs in machine learning. He developed a neural tangent hierarchy framework that makes it possible to study the training dynamics of deep neural networks with characteristics that are reflective of real-world, scalable systems. Huang has recently started a faculty position at the University of Pennsylvania.


James Daniel Brandenburg, PhD, nominated by Brookhaven National Laboratory

Particle physicist Dr. James Daniel Brandenburg has made extraordinary experimental achievements at the frontier of high-energy nuclear physics that are changing our understanding of the properties of light and matter. At Brookhaven National Laboratory, Brandenburg uses the Relativistic Heavy-Ion Collider (RHIC) to investigate the properties of subatomic particles, like quarks and gluons, which are the essential building blocks of visible matter (i.e., protons and neutrons). His work led to the very first experimental observation of the famous Breit-Wheeler process—the simplest physical process by which photons of light are converted into matter. Brandenburg is also credited with a number of other notable discoveries in experimental high-energy physics.




Rosemary Cater, PhD, nominated by Columbia University

Structural biologist Dr. Rosemary Cater has uncovered how omega-3 fatty acids cross the blood-brain barrier (BBB) and is creating new possibilities for delivering neurotherapeutics into the brain. The BBB is a highly selective layer of cells that protects the nervous system from damage but also blocks the vast majority of potential neurotherapeutic drugs from accessing the brain. Cater is the first to identify the molecular structure of a key protein that transports omega-3 fatty acids across the BBB, and in so doing, provides a template to design drugs that mimic those biomolecules to access the brain. She has also demonstrated how other proteins in the brain can serve multiple roles at once to control neurotransmission. Her work opens a host of new possibilities for drugs and treatments targeting neurological disorders.


Shuai Gao, PhD, nominated by Princeton University

Structural biologist Dr. Shuai Gao has shed new light on how ions are transported in the body, understanding in new detail how cells behave, and opening new directions for drug development. The channels that shuttle ions into and out of cells are key to a wide range of bodily functions, from facilitating neurological responses like pain to regulating cell behavior. Gao is harnessing innovative strategies to measure the atomic structure of several ion channels that are key to sensing pain. By revealing the molecular basis for how pain relief agents work, Gao is offering new strategies for developing drugs that provide non-addictive pain relief. He has recently joined the faculty at Wuhan University in China.


About the Blavatnik Awards for Young Scientists

The Blavatnik Awards for Young Scientists, established by the Blavatnik Family Foundation in 2007 and independently administered by the New York Academy of Sciences, initially identified outstanding regional scientific talent among faculty and postdoctoral students in New York, New Jersey, and Connecticut. The Blavatnik National Awards, honoring faculty-rank scientists throughout the United States, were first awarded in 2014 and were expanded in 2017 to honor faculty-rank scientists in the United Kingdom and Israel. By the end of 2022, the Blavatnik Awards will have awarded prizes totaling $13.6 million and, to date, has honored over 392 scientists. Visit for further information.


About the Blavatnik Family Foundation

The Blavatnik Family Foundation is an active supporter of world-renowned educational, scientific, cultural, and charitable institutions in the United States, the United Kingdom, Israel, and other countries. The foundation is headed by Len Blavatnik, a businessman, philanthropist, and founder and chairman of Access Industries, a privately held industrial group based in the U.S. with global strategic interests.

Visit or for more information.


About the New York Academy of Sciences

The New York Academy of Sciences is an independent, not-for-profit organization that has been committed to advancing science for the benefit of society since 1817. With more than 20,000 members in 100 countries, the Academy advances scientific and technical knowledge, addresses global challenges with science-based solutions, and sponsors a wide variety of educational initiatives at all levels for STEM and STEM-related fields. The Academy hosts programs and publishes content in the life and physical sciences, the social sciences, nutrition, artificial intelligence, computer science, and sustainability. The Academy also provides professional and educational resources for researchers across all phases of their careers. Please visit us online at


Media contact

Kamala Murthy,, 212-298-3740


Read More

Continue Reading


Gonorrhea became more drug resistant while attention was on COVID-19 – a molecular biologist explains the sexually transmitted superbug

The US currently has only one antibiotic available to treat gonorrhea – and it’s becoming less effective.




The _Neisseria gonorrhoeae_ bacterium causes gonorrhea by infecting mucous membranes. Design Cells/iStock Getty Images Plus via Getty Images

COVID-19 has rightfully dominated infectious disease news since 2020. However, that doesn’t mean other infectious diseases took a break. In fact, U.S. rates of infection by gonorrhea have risen during the pandemic.

Unlike COVID-19, which is a new virus, gonorrhea is an ancient disease. The first known reports of gonorrhea date from China in 2600 BC, and the disease has plagued humans ever since. Gonorrhea has long been one of the most commonly reported bacterial infections in the U.S.. It is caused by the bacterium Neisseria gonorrhoeae, which can infect mucous membranes in the genitals, rectum, throat and eyes.

Gonorrhea is typically transmitted by sexual contact. It is sometimes referred to as “the clap.”

Prior to the pandemic, there were around 1.6 million new gonorrhea infections each year. Over 50% of those cases involved strains of gonorrhea that had become unresponsive to treatment with at least one antibiotic.

In 2020, gonorrhea infections initially went down 30%, most likely due to pandemic lockdowns and social distancing. However, by the end of 2020 – the last year for which data from the Centers for Disease Control and Prevention is available – reported infections were up 10% from 2019.

It is unclear why infections went up even though some social distancing measures were still in place. But the CDC notes that reduced access to health care may have led to longer infections and more opportunity to spread the disease, and sexual activity may have increased when initial shelter-in-place orders were lifted.

As a molecular biologist, I have been studying bacteria and working to develop new antibiotics to treat drug-resistant infections for 20 years. Over that time, I’ve seen the problem of antibiotic resistance take on new urgency.

Gonorrhea, in particular, is a major public health concern, but there are concrete steps that people can take to prevent it from getting worse, and new antibiotics and vaccines may improve care in the future.

How to recognize gonorrhea

Around half of gonorrhea infections are asymptomatic and can only be detected through screening. Infected people without symptoms can unknowingly spread gonorrhea to others.

Typical early signs of symptomatic gonorrhea include a painful or burning sensation when peeing, vaginal or penal discharge, or anal itching, bleeding or discharge. Left untreated, gonorrhea can cause blindness and infertility. Antibiotic treatment can cure most cases of gonorrhea as long as the infection is susceptible to at least one antibiotic.

There is currently only one recommended treatment for gonorrhea in the U.S. – an antibiotic called ceftriaxone – because the bacteria have become resistant to other antibiotics that were formerly effective against it. Seven different families of antibiotics have been used to treat gonorrhea in the past, but many strains are now resistant to one or more of these drugs.

The CDC tracks the emergence and spread of drug-resistant gonorrhea strains.

Why gonorrhea is on the rise

A few factors have contributed to the increase in infections during the COVID-19 pandemic.

Early in the pandemic, most U.S. labs capable of testing for gonorrhea switched to testing for COVID-19. These labs have also been contending with the same shortages of staff and supplies that affect medical facilities across the country.

Many people have avoided clinics and hospitals during the pandemic, which has decreased opportunities to identify and treat gonorrhea infections before they spread. In fact, because of decreased screening over the past two and a half years, health care experts don’t know exactly how much antibiotic-resistant gonorrhea has spread.

Also, early in the pandemic, many doctors prescribed antibiotics to COVID-19 patients even though antibiotics do not work on viruses like SARS-CoV-2, the virus that causes COVID-19. Improper use of antibiotics can contribute to greater drug resistance, so it is reasonable to suspect that this has happened with gonorrhea.

Overuse of antibiotics

Even prior to the pandemic, resistance to antibiotic treatment for bacterial infections was a growing problem. In the U.S., antibiotic-resistant gonorrhea infections increased by over 70% from 2017-2019.

Neisseria gonorrhoeae is a specialist at picking up new genes from other pathogens and from “commensal,” or helpful, bacteria. These helpful bacteria can also become antibiotic-resistant, providing more opportunities for the gonorrhea bacterium to acquire resistant genes.

Strains resistant to ceftriaxone have been observed in other countries, including Japan, Thailand, Australia and the U.K., raising the possibility that some gonorrhea infections may soon be completely untreatable.

Steps toward prevention

Currently, changes in behavior are among the best ways to limit overall gonorrhea infections – particularly safer sexual behavior and condom use.

However, additional efforts are needed to delay or prevent an era of untreatable gonorrhea.

Scientists can create new antibiotics that are effective against resistant strains; however, decreased investment in this research and development over the past 30 years has slowed the introduction of new antibiotics to a trickle. No new drugs to treat gonorrhea have been introduced since 2019, although two are in the final stage of clinical trials.

Vaccination against gonorrhea isn’t possible presently, but it could be in the future. Vaccines effective against the meningitis bacterium, a close relative of gonorrhea, can sometimes also provide protection against gonorrhea. This suggests that a gonorrhea vaccine should be achievable.

The World Health Organization has begun an initiative to reduce gonorrhea worldwide by 90% before 2030. This initiative aims to promote safe sexual practices, increase access to high-quality health care for sexually transmitted diseases and expand testing so that asymptomatic infections can be treated before they spread. The initiative is also advocating for increased research into vaccines and new antibiotics to treat gonorrhea.

Setbacks in fighting drug-resistant gonorrhea during the COVID-19 pandemic make these actions even more urgent.

Kenneth Keiler receives funding from NIH.

Read More

Continue Reading

Spread & Containment

Measuring the Ampleness of Reserves

Over the past fifteen years, reserves in the banking system have grown from tens of billions of dollars to several trillion dollars. This extraordinary…



Over the past fifteen years, reserves in the banking system have grown from tens of billions of dollars to several trillion dollars. This extraordinary rise poses a natural question: Are the rates paid in the market for reserves still sensitive to changes in the quantity of reserves when aggregate reserve holdings are so large? In today’s post, we answer this question by estimating the slope of the reserve demand curve from 2010 to 2022, when reserves ranged from $1 trillion to $4 trillion.

What Are Reserves? And Why Do They Matter?

Banks hold accounts at the Federal Reserve where they keep cash balances called “reserves.” Reserves meet banks’ various needs, including making payments to other financial institutions and meeting regulatory requirements. Over the past fifteen years, reserves have grown enormously, from tens of billions of dollars in 2007 to $3 trillion today. The chart below shows the evolution of reserves in the U.S. banking system as a share of banks’ total assets from January 2010 through September 2022. The supply of reserves depends importantly on the actions of the Federal Reserve, which can increase or decrease the quantity of reserves by changing its securities holdings, as it did in response to the global financial crisis and the COVID-19 crisis.

Reserves Have Ranged from 8 to 19 Percent of Bank Assets from 2010 to 2022

Sources: Federal Reserve Bank of New York; Federal Reserve Economic Data, FRED (“TLAACBW027SBOG”); authors’ calculations.

Why does the quantity of reserves matter? Because the “price” at which banks trade their reserve balances, which in turn depends importantly on the total amount of reserves in the system, is the federal funds rate, which is the interest rate targeted by the Federal Open Market Committee (FOMC) in the implementation of monetary policy. In 2022, the FOMC stated that “over time, the Committee intends to maintain securities holdings in amounts needed to implement monetary policy efficiently and effectively in its ample reserves regime.” In this ample reserves regime, the Federal Reserve controls short-term interest rates mainly through the setting of administered rates, rather than by adjusting the supply of reserves each day as it did prior to 2008 (as discussed in this post). In today’s post, we describe a method to measure the sensitivity of interest rates to changes in the quantity of reserves that can serve as a useful indicator of whether the level of reserves is ample.

The Demand for Reserves Informs Us about Rate Sensitivity to Reserve Shocks

To assess whether the level of reserves is ample, one needs to first understand the demand for reserves. Banks borrow and lend in the market for reserves, typically overnight. The reserve demand curve describes the price at which these institutions are willing to trade their balances as a function of aggregate reserves. Its slope measures the price sensitivity to changes in the level of reserves. Importantly, banks earn interest on their reserve balances (IORB), set by the Federal Reserve. Because the IORB rate directly affects the willingness of banks to lend reserves, it is useful to describe the reserve demand curve in terms of the spread between the federal funds rate and the IORB rate. In addition, we control for the overall growth of the U.S. banking sector by specifying reserve demand in terms of the level of reserves relative to commercial banks’ assets.

There is a clear nonlinear downward-sloping relationship between prices and quantities of reserves, consistent with economic theory. The chart below plots the spread between the federal funds rate and the IORB against total reserves as a share of commercial banks’ total assets.  When reserves are very low, the demand curve has a steep negative slope, reflecting the willingness of borrowers to pay high rates because reserves are scarce. At the other extreme, when reserves are very high, the curve becomes flat because banks are awash with reserves and the supply is abundant. Between these two regions, an intermediate regime–that we refer to as “ample”–emerges, where the demand curve exhibits a modest downward slope. The color coding of the chart reflects the shifts in the reserve demand curve over time. In particular, the curve appears to have moved to the right and upward around 2015 and then moved upward after March 2020, at the onset of the COVID pandemic.

Reserve Demand Has Shifted over Time

Sources: Federal Reserve Bank of New York; Federal Reserve Economic Data, FRED (“TLAACBW027SBOG,” “IOER,” and “IORB”); authors’ calculations.

This chart highlights two of the main challenges in estimating the slope of the reserve demand curve. First, the curve is highly nonlinear, which means that a standard linear estimation approach is not appropriate. Second, various long-lasting changes in the regulation and supervision of banks, in their internal risk-management frameworks, and in the structure of the reserve market itself have resulted in shifts in the reserve demand curve. A third challenge is that the quantity of reserves may be endogenous to banks’ demand for them. Therefore, to properly measure the reserve demand curve, one must disentangle shocks to supply from those to demand. As we explain in detail in a recent paper, our estimation strategy addresses all three of these challenges.

Estimating the Slope of the Reserve Demand Curve

Our approach provides time-varying estimates of the price sensitivity of the demand for reserves that can be used to distinguish between periods in which reserves are relatively scarce, ample, or abundant. The chart below presents our daily estimates of the slope of the demand curve, as measured by the rate sensitivity to changes in reserves. Although we do not have a precise criterion for when reserves are scarce versus ample, during two episodes in our sample, the estimated rate sensitivity is well away from zero. The first episode occurs early in our sample, in 2010, and the second emerges almost ten years later, in mid-2019. In two other periods—during 2013-2017 and from mid-2020 through early September 2022—the estimated slope is very close to zero, indicating an abundance of reserves. The remaining periods are characterized by a modest negative slope of the reserve demand curve, consistent with ample (but short of abundant) reserves. The overall pattern of these estimates is robust to changes in the model specification, such as including spillovers from the repo and Treasury markets or measuring reserves as a share of gross domestic product or bank deposits (instead of as a share of banks’ assets).

Rate Sensitivity Changed over Time, Following the Path of Reserves

Sources: Federal Reserve Bank of New York; Federal Reserve Economic Data, FRED (“TLAACBW027SBOG,” “IOER,” and “IORB”); authors’ calculations.

Interest Rate Spreads Alone Are Not Reliable Indicators of Reserve Scarcity

As we discuss in our paper, the time variation in the estimated price sensitivity in the demand for reserves is based on observations of small movements along the demand curve due to exogenous supply shocks. The location of the curve itself, however, also changes over time. That is, there is not a constant relationship between the level of reserves and the slope of the reserve demand curve.  

In our paper, we find evidence of both horizontal and vertical shifts in the reserve demand curve, with vertical upward shifts being particularly important since 2015. This finding implies that the level of the federal funds-IORB spread may not be a reliable summary statistic for the sensitivity of interest rates to reserve shocks, and that estimates of the price sensitivity in the demand for reserves provide additional useful information.

In summary, we have developed a method to estimate the time-varying interest rate sensitivity of the demand for reserves that accounts for the nonlinear nature of reserve demand and allows for structural shifts over time. A key advantage of our methodology is that it provides a flexible and readily implementable approach that can be used to monitor the market for reserves in real time, allowing one to assess the “ampleness” of the reserve supply as market conditions evolve.

Gara Afonso is the head of Banking Studies in the Federal Reserve Bank of New York’s Research and Statistics Group.

Gabriele La Spada is a financial research economist in Money and Payments Studies in the Federal Reserve Bank of New York’s Research and Statistics Group.   

John C. Williams is the president and chief executive officer of the Federal Reserve Bank of New York.  

How to cite this post:
Gara Afonso, Gabriele La Spada, and John C. Williams, “Measuring the Ampleness of Reserves,” Federal Reserve Bank of New York Liberty Street Economics, October 5, 2022,

The views expressed in this post are those of the author(s) and do not necessarily reflect the position of the Federal Reserve Bank of New York or the Federal Reserve System. Any errors or omissions are the responsibility of the author(s).

Read More

Continue Reading


Vir awarded $1 billion multi-year BARDA influenza contract

The US Government’s Biomedical Advanced Research and Development Authority (BARDA) has made an initial investment of approximately $55
The post Vir awarded…



The US Government’s Biomedical Advanced Research and Development Authority (BARDA) has made an initial investment of approximately $55 million for rapid development of VIR-2482, the Vir Biotechnology’s investigational prophylactic monoclonal antibody (mAb) for seasonal and pandemic influenza viruses.

Its purpose being to support pandemic preparedness for influenza and other infectious disease threats, this is the first award from BARDA – part of the US Department of Health and Human Services’ (HHS) Administration for Strategic Preparedness and Response (ASPR) – for pre-exposure prophylaxis for influenza.

VIR-2482 is an investigational intramuscularly administered influenza A-neutralising mAb. It has been shown in vitro to cover all major influenza A strains that have arisen since the 1918 ‘Spanish flu’ pandemic and is designed as a universal prophylactic for influenza A.

Furthermore, VIR-2482 could have the potential to overcome the limitations of current flu vaccines and result in higher levels of protection, given it does not rely on an individual to create their own protective antibody response. Additionally, the incorporated Xencor Xtend Technology is half-life engineered, meaning a single dose could potentially last an entire flu season.

Seasonal influenza (or flu) is a highly contagious respiratory disease that can cause severe illness and life-threatening complications. In just the past few years, seasonal influenza has resulted in around 4 million hospitalisations and circa 500,000 global annual deaths.

Pandemic influenza, by contrast, is a contagious airborne respiratory disease with unpredictable timing and severity and against which humans have little or no immunity. Four such pandemic influenzas have occurred in only the past century, with the 1918 ‘Spanish flu’ alone having resulted in 50 million deaths worldwide.

Given the past two years’ and ongoing experience with SARS-CoV-2 and its variants, the BARDA multi-year contract – potentially an investment of up to $1 billion in total – aims to continue the Authority’s efforts in preparing for and responding to public health emergencies. Currently, there is a significant unmet need to address shortcomings in preventative and therapeutic options for influenza, the efficacy of the present options that do exist ranging from only 10% to 60%.

Therefore, this initial $55 million investment aims to address these shortcomings. It includes for a phase 2 pre-exposure prophylaxis trial, to begin this second half of the year, with initial data expected by mid-2023. The balance of the award is subject to up to 12 options being exercised by BARDA in further support of the development of pre-exposure prophylactic antibodies, including and beyond VIR-2482.

This extended area, beyond prevention of influenza illness, will potentially be for supportive medical countermeasures for up to 10 “other pathogens of pandemic potential”, whether they be “chemical, biological, radiological [or] nuclear”.

Dr Rajesh Gupta, vice president, global health portfolio and public-private partnerships at Vir Biotechnology, said: “COVID-19 reinforced the ever-present global threat of infectious diseases, and the critical need for readily available solutions in advance of the next pandemic.”

A commercial-stage immunology company, Vir Biotechnology’s current development pipeline includes product candidates targeting hepatitis B and hepatitis D viruses and human immunodeficiency virus, in addition to influenza A and COVID-19, the latter of which Vir (together with GSK) previously delivered the antibody sotrovimab (Xevudy) for. The company also co-discovered ansuvimab-zykl for addressing the Ebola crisis.

Bolyn Hubby, PhD, executive vice president and chief corporate affairs officer at Vir Biotechnology, said: “Just as the COVID-19 pandemic required unprecedented cross-sector collaboration around the globe, tackling the outbreaks and pandemics of tomorrow will require an ‘all hands on deck’ approach that unites a broad array of public and private organisations.”

Under a collaboration agreement signed with GlaxoSmithKline (GSK) in 2021, GSK holds an exclusive option to lead post-phase 2 development and commercialisation of VIR-2482.

The post Vir awarded $1 billion multi-year BARDA influenza contract appeared first on .

Read More

Continue Reading